KYTX earnings date and last-quarter result: next report 2026-08-11, last quarter beat, P/E -2.26. Updated 2026-07-23.
Kyverna Therapeutics (KYTX) Research Hub
Kyverna Therapeutics (KYTX) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 5.27 USD (-2.23%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -2.26, market cap 0.32B. This hub links to the full technical, earnings and options research available for KYTX.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 5.27 USD (-2.23%) |
| 52-week range | 5.18 USD – 10.19 USD |
| Trend regime | Range |
| 14-day RSI | 33.3 (Bearish) |
| Trailing P/E | -2.26 |
| Market cap | 0.32B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-11 |
Available research for KYTX
Covered Call on KYTX: how it works, illustrative setup around the real 5.27 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on KYTX: how it works, illustrative setup around the real 5.27 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on KYTX: how it works, illustrative setup around the real 5.27 USD price, max profit/loss, breakeven and when to use it. Educational.
KYTX technical analysis: range, last 5.27 USD, RSI 33.3, 52w range 5.18 USD–10.19 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is KYTX in?
Kyverna Therapeutics (KYTX) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is KYTX in an uptrend or downtrend?
As of 2026-10-26, KYTX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is KYTX's trailing P/E ratio?
KYTX's trailing P/E is -2.26, with a market cap of 0.32B. See the earnings research page for full valuation detail.
When does KYTX next report earnings?
KYTX is next scheduled to report earnings on 2026-08-11.